Unveiling Gut Homeostasis Disruption in Sepsis: Towards an Integrated Mechanistic and Translational Roadmap

Abstract

Sepsis, a life-threatening clinical syndrome precipitated by a maladaptive host response to infection, is associated with substantial morbidity and high mortality rates. Gastrointestinal injury has gained recognition as a pivotal factor driving sepsis progression. Pathogen invasion incites oxidative stress and inflammatory cascades, leading to compromised intestinal barrier integrity and dysregulated local immunity. This results in increased gut permeability and bacterial translocation, fostering a state that can be described as ‘enteric sepsis’. Moreover, multi-organ crosstalk via the gut-liver and gut-brain axes substantially amplifies systemic inflammation. The pathophysiology of sepsis-induced intestinal injury is not yet fully elucidated, and clinically applicable biomarkers or early diagnostic tools remain scarce. Targeted therapeutic strategies have yet to be validated in clinical practice. This article presents a comprehensive review of recent advances in the pathophysiology and underlying mechanisms of sepsis-induced intestinal injury, focusing on the signalling networks that disrupt intestinal homeostasis and immune equilibrium. Particular emphasis is placed on identifying key pathways and candidate biomarkers for early diagnosis and intervention. Additionally, the therapeutic potential of targeted intestinal-protective agents is evaluated, integrating insights from traditional Chinese medicine to propose a combined treatment strategy. Ultimately, this review aims to establish a translational framework to advance clinical management and therapeutic innovation for sepsis-associated intestinal dysfunction.

Keywords

bacterial translocation / dysregulation of immunity / gut-target axis / intestinal barrier / sepsis / sepsis-induced intestinal injury

References

[1] M. Singer, C. S. Deutschman, C. W. Seymour, et al., “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3),” Journal of the American Medical Association 315, no. 8 (2016): 801–810.

[2] A. P. Gray, E. Chung, R. L. Hsu, et al., “Global, Regional, and National Sepsis Incidence and Mortality, 1990–2021: A Systematic Analysis,” Lancet Global Health 13, no. 12 (2025): E2013–E2026, https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00356-0/fulltext.

[3] C. Magnan, T. Lancry, F. Salipante, et al., “Role of Gut Microbiota and Bacterial Translocation in Acute Intestinal Injury and Mortality in Patients Admitted in ICU for Septic Shock,” Frontiers in Cellular and Infection Microbiology 13 (2023): 1330900.

[4] J. M. O'Brien, N. A. Ali, S. K. Aberegg, and E. Abraham, “Sepsis,” American Journal of Medicine 120, no. 12 (2007): 1012–1022.

[5] P. Morgan and A. Majeed, “Sepsis: Getting the Balance Right,” BMJ 28, no. 367 (2019): l6700.

[6] L. Thoo, M. Noti, and P. Krebs, “Keep Calm: The Intestinal Barrier at the Interface of Peace and War,” Cell Death & Disease 10, no. 11 (2019): 849.

[7] P. R. Kiela, D. Laubitz, C. B. Larmonier, et al., “Changes in Mucosal Homeostasis Predispose NHE3 Knockout Mice to Increased Susceptibility to DSS-Induced Epithelial Injury,” Gastroenterology 137, no. 3 (2009): 965–975, 975.e1-10.

[8] X. Zhang, H. Liu, K. Hashimoto, S. Yuan, and J. Zhang, “The Gut–Liver Axis in Sepsis: Interaction Mechanisms and Therapeutic Potential,” Critical Care 13, no. 26 (2022): 213.

[9] D. Qiu, W. Zhang, Z. Song, et al., “Berberine Suppresses Cecal Ligation and Puncture Induced Intestinal Injury by Enhancing Treg Cell Function,” International Immunopharmacology 106 (2022): 108564.

[10] Z. Wen, X. Xiong, D. Chen, et al., “Activating Transcription Factor 4 Protects Mice Against Sepsis-Induced Intestinal Injury by Regulating Gut-Resident Macrophages Differentiation,” Chinese Medical Journal 135, no. 21 (2022): 2585–2595.

[11] A. Wallrapp and I. M. Chiu, “Neuroimmune Interactions in the Intestine,” Annual Review of Immunology 42, no. 1 (2024): 489–519.

[12] A. Lockhart, D. Mucida, and R. Parsa, “Immunity to Enteric Viruses,” Immunity 55, no. 5 (2022): 800–818.

[13] H. Tilg, T. E. Adolph, and M. Trauner, “Gut-Liver Axis: Pathophysiological Concepts and Clinical Implications,” Cell Metabolism 34, no. 11 (2022): 1700–1718.

[14] L. G. van der Flier and H. Clevers, “Stem Cells, Self-Renewal, and Differentiation in the Intestinal Epithelium,” Annual Review of Physiology 71 (2009): 241–260.

[15] N. Barker, “Adult Intestinal Stem Cells: Critical Drivers of Epithelial Homeostasis and Regeneration,” Nature Reviews. Molecular Cell Biology 15, no. 1 (2014): 19–33.

[16] H. Gehart and H. Clevers, “Tales From the Crypt: New Insights Into Intestinal Stem Cells,” Nature Reviews. Gastroenterology & Hepatology 16, no. 1 (2019): 19–34.

[17] T. Takahashi, K. Fujishima, and M. Kengaku, “Modeling Intestinal Stem Cell Function With Organoids,” International Journal of Molecular Sciences 22, no. 20 (2021): 10912.

[18] J. V. Patankar and C. Becker, “Cell Death in the Gut Epithelium and Implications for Chronic Inflammation,” Nature Reviews. Gastroenterology & Hepatology 17, no. 9 (2020): 543–556.

[19] I. Martin-Loeches, M. Singer, and M. Leone, “Sepsis: Key Insights, Future Directions, and Immediate Goals. A Review and Expert Opinion,” Intensive Care Medicine 50, no. 12 (2024): 2043–2049.

[20] L. Liu, Q. Yue, J. Chen, H. Liu, and X. Zeng, “Intestinal Injury Signaling Pathway in Sepsis,” Frontiers in Immunology 27, no. 16 (2025): 1620965.

[21] G. Piton and G. Capellier, “Biomarkers of Gut Barrier Failure in the ICU,” Current Opinion in Critical Care 22, no. 2 (2016): 152–160.

[22] Y. Jiang, Y. Bian, N. Lian, et al., “iTRAQ-Based Quantitative Proteomic Analysis of Intestines in Murine Polymicrobial Sepsis With Hydrogen Gas Treatment,” Drug Design, Development and Therapy 14 (2020): 4885–4900.

[23] F. Mustansir Dawoodbhoy, B. K. Patel, K. Patel, M. Bhatia, C. N. Lee, and S. M. Moochhala, “Gut Microbiota Dysbiosis as a Target for Improved Post-Surgical Outcomes and Improved Patient Care: A Review of Current Literature,” Shock 55, no. 4 (2021): 441–454.

[24] R. Saadia, “Trauma and Bacterial Translocation,” British Journal of Surgery 82, no. 9 (1995): 1243–1244.

[25] M. Ziaka and A. Exadaktylos, “Gut-Derived Immune Cells and the Gut-Lung Axis in ARDS,” Critical Care 28, no. 1 (2024): 220.

[26] K. F. Budden, S. L. Gellatly, D. L. A. Wood, et al., “Emerging Pathogenic Links Between Microbiota and the Gut-Lung Axis,” Nature Reviews. Microbiology 15, no. 1 (2017): 55–63.

[27] R. P. Dickson, “The Microbiome and Critical Illness,” Lancet Respiratory Medicine 4, no. 1 (2016): 59–72.

[28] K. T. Fay, M. L. Ford, and C. M. Coopersmith, “The Intestinal Microenvironment in Sepsis,” Biochimica et Biophysica Acta, Molecular Basis of Disease 1863, no. 10 Pt B (2017): 2574–2583.

[29] N. Arpaia, C. Campbell, X. Fan, et al., “Metabolites Produced by Commensal Bacteria Promote Peripheral Regulatory T-Cell Generation,” Nature 504, no. 7480 (2013): 451–455.

[30] M. Cecconi, L. Evans, M. Levy, and A. Rhodes, “Sepsis and Septic Shock,” Lancet 392 (2018): 75–87.

[31] T. Srdić, S. Đurašević, I. Lakić, et al., “From Molecular Mechanisms to Clinical Therapy: Understanding Sepsis-Induced Multiple Organ Dysfunction,” International Journal of Molecular Sciences 25 (2024): 7770.

[32] X. Lou, J. Xue, R. Shao, et al., “Fecal Microbiota Transplantation and Short-Chain Fatty Acids Reduce Sepsis Mortality by Remodeling Antibiotic-Induced Gut Microbiota Disturbances,” Frontiers in Immunology 13 (2023): 1063543.

[33] C. de la Fuente-Nunez, A. Cesaro, and R. E. W. Hancock, “Antibiotic Failure: Beyond Antimicrobial Resistance,” Drug Resistance Updates 71 (2023): 101012.

[34] A. Rhodes, L. E. Evans, W. Alhazzani, et al., “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016,” Intensive Care Medicine 43 (2017): 304–377.

[35] B. W. Haak and W. J. Wiersinga, “The Role of the Gut Microbiota in Sepsis,” Lancet Gastroenterology & Hepatology 2 (2017): 135–143.

[36] D.-C. Chen, “Sepsis and Intestinal Microvascular Endothelial Dysfunction,” Chinese Medical Journal 130 (2017): 1137–1138.

[37] Y. Xu, J. Wang, R. Yuan, Z. Qin, K. Long, and P. Gao, “Targeting the Immuno-Inflammatory-Microbial Network: A Key Strategy for Sepsis Treatment,” Frontiers in Immunology 16 (2025): 1575516.

[38] Y. Li, D. Feng, Z. Wang, et al., “Ischemia-Induced ACSL4 Activation Contributes to Ferroptosis-Mediated Tissue Injury in Intestinal Ischemia/Reperfusion,” Cell Death and Differentiation 26 (2019): 2284–2299.

[39] D. N. Granger and P. R. Kvietys, “Reperfusion Injury and Reactive Oxygen Species: The Evolution of a Concept,” Redox Biology 6 (2015): 524–551.

[40] X. Zhang, J. Wu, Q. Liu, et al., “mtDNA-STING Pathway Promotes Necroptosis-Dependent Enterocyte Injury in Intestinal Ischemia Reperfusion,” Cell Death & Disease 11 (2020): 1050.

[41] S. Lv, C. Ma, W. Fu, et al., “Electroacupuncture Alleviates Intestinal Ischemia-Reperfusion-Induced Acute Lung Injury via the Vagus-Sympathetic Nerve Pathway,” International Immunopharmacology 165 (2025): 115484.

[42] M. Palmier, S. Fraineau, A. Sutton, H. Hlawaty, J. Bellien, and D. Plissonnier, “The Pathophysiology of Acute Lung Injury Following Intestinal Ischemia-Reperfusion,” American Journal of Physiology. Lung Cellular and Molecular Physiology 329 (2025): L397–L418.

[43] X. Xu, X. Huang, L. Xiao, J. Wang, X. Yang, and Y. Wu, “Mechanism of Electro-Acupuncture in Alleviating Intestinal Injury in Septic Mice via Polyamine-Related M2-Macrophage Polarization,” Frontiers in Immunology 15 (2024): 1373876.

[44] D. J. Hausenloy and D. M. Yellon, “Myocardial Ischemia-Reperfusion Injury: A Neglected Therapeutic Target,” Journal of Clinical Investigation 123 (2013): 92–100.

[45] F.-L. Zhang, Z. Hu, Y. F. Wang, et al., “Organoids Transplantation Attenuates Intestinal Ischemia/Reperfusion Injury in Mice Through L-Malic Acid-Mediated M2 Macrophage Polarization,” Nature Communications 14 (2023): 6779.

[46] J. Hu, F. Deng, B. Zhao, et al., “Lactobacillus murinus Alleviate Intestinal Ischemia/Reperfusion Injury Through Promoting the Release of Interleukin-10 From M2 Macrophages via Toll-Like Receptor 2 Signaling,” Microbiome 10 (2022): 38.

[47] Y. Chen, B. Han, X. Guan, et al., “Enteric Fungi Protect Against Intestinal Ischemia-Reperfusion Injury via Inhibiting the SAA1-GSDMD Pathway,” Journal of Advanced Research 61 (2024): 223–237.

[48] F. Deng, B. C. Zhao, X. Yang, et al., “The Gut Microbiota Metabolite Capsiate Promotes Gpx4 Expression by Activating TRPV1 to Inhibit Intestinal Ischemia Reperfusion-Induced Ferroptosis,” Gut Microbes 13 (2021): 1–21.

[49] F.-L. Zhang, X.-W. Chen, Y.-F. Wang, et al., “Microbiota-Derived Tryptophan Metabolites Indole-3-Lactic Acid Is Associated With Intestinal Ischemia/Reperfusion Injury via Positive Regulation of YAP and Nrf2,” Journal of Translational Medicine 21 (2023): 234.

[50] M. Hou, X. Li, F. Chen, et al., “Naringenin Alleviates Intestinal Ischemia/Reperfusion Injury by Inhibiting Ferroptosis via Targeting YAP/STAT3 Signaling Axis,” Phytomedicine 135 (2024): 156095.

[51] S. Deng, H. Cao, T. Li, et al., “Lachnospiraceae-Bacterium Alleviates Ischemia-Reperfusion Injury in Steatotic Donor Liver by Inhibiting Ferroptosis via the Foxo3-Alox15 Signaling Pathway,” Gut Microbes 17 (2025): 2460543.

[52] X. Zhao, D. Liu, Y. Zhao, et al., “HRD1-Induced TMEM2 Ubiquitination Promotes ER Stress-Mediated Apoptosis Through a Non-Canonical Pathway in Intestinal Ischemia/Reperfusion,” Cell Death & Disease 15 (2024): 154.

[53] J. Yuan and D. Ofengeim, “A Guide to Cell Death Pathways,” Nature Reviews. Molecular Cell Biology 25 (2024): 379–395.

[54] M. E. Delgado, T. Grabinger, and T. Brunner, “Cell Death at the Intestinal Epithelial Front Line,” FEBS Journal 283 (2016): 2701–2719.

[55] K. Ping, R. Yang, H. Chen, et al., “Gypenoside XLIX Alleviates Intestinal Injury by Inhibiting Sepsis-Induced Inflammation, Oxidative Stress, Apoptosis, and Autophagy,” Chemico-Biological Interactions 397 (2024): 111077.

[56] Y. Bao, X. Yang, P. Zhao, and X. Du, “Research Advances on the Role of Programmed Endothelial Cell Death in Sepsis,” Cell Death Discov 11 (2025): 426.

[57] Z. Yan, L. Niu, S. Wang, C. Gao, and S. Pan, “Intestinal Piezo1 Aggravates Intestinal Barrier Dysfunction During Sepsis by Mediating Ca2+ Influx,” Journal of Translational Medicine 22 (2024): 332.

[58] M. F. Neurath, D. Artis, and C. Becker, “The Intestinal Barrier: A Pivotal Role in Health, Inflammation, and Cancer,” Lancet Gastroenterology & Hepatology 10 (2025): 573–592.

[59] P. Mandal, Y. Feng, J. D. Lyons, et al., “Caspase-8 Collaborates With Caspase-11 to Drive Tissue Damage and Execution of Endotoxic Shock,” Immunity 49 (2018): 42–55.e6.

[60] S. Christgen, R. E. Tweedell, and T.-D. Kanneganti, “Programming Inflammatory Cell Death for Therapy,” Pharmacology & Therapeutics 232 (2022): 108010.

[61] P. Zhou, S. Zhang, M. Wang, and J. Zhou, “The Induction Mechanism of Ferroptosis, Necroptosis, and Pyroptosis in Inflammatory Bowel Disease, Colorectal Cancer, and Intestinal Injury,” Biomolecules 13 (2023): 820.

[62] C. Chu, X. Wang, C. Yang, et al., “Neutrophil Extracellular Traps Drive Intestinal Microvascular Endothelial Ferroptosis by Impairing Fundc1-Dependent Mitophagy,” Redox Biology 67 (2023): 102906.

[63] A. Bergmann, “Erebosis Is a New Type of Cell Death for Tissue Homeostasis in the Drosophila Intestine,” PLoS Biology 20 (2022): e3001614.

[64] A. Pandeya and T.-D. Kanneganti, “Therapeutic Potential of PANoptosis: Innate Sensors, Inflammasomes, and RIPKs in PANoptosomes,” Trends in Molecular Medicine 30 (2024): 74–88.

[65] X. He, X. Jiang, J. Guo, H. Sun, and J. Yang, “PANoptosis in Bacterial Infections: A Double-Edged Sword Balancing Host Immunity and Pathogenesis,” Pathogens 14 (2025): 43.

[66] L. Qi, B. Lan, Z. Zhao, et al., “Research Advances of PANoptosis in Gastrointestinal Tumors,” International Immunopharmacology 159 (2025): 114931.

[67] J.-F. Lin, P. S. Hu, Y. Y. Wang, et al., “Phosphorylated NFS1 Weakens Oxaliplatin-Based Chemosensitivity of Colorectal Cancer by Preventing PANoptosis,” Signal Transduction and Targeted Therapy 7 (2022): 54.

[68] C. Wu, H. Miao, Z. Yi, et al., “STING-Mediated Mitochondrial DNA Release Exacerbates PANoptosis in Liver Ischemia Reperfusion Injury,” International Immunopharmacology 157 (2025): 114778.

[69] H. Yuan, L. Zhou, Y. Chen, et al., “Salmonella Effector SopF Regulates PANoptosis of Intestinal Epithelial Cells to Aggravate Systemic Infection,” Gut Microbes 15 (2023): 2180315.

[70] C. Tan, Z. Xiang, S. Wang, et al., “Diosmin Alleviates Colitis by Inhibiting PANoptosis of Intestinal Epithelial Cells and Regulating Gut Microbiota and Metabolites,” Phytomedicine 141 (2025): 156671.

[71] Y. Wang, H. Zhang, and C. Miao, “Unraveling Immunosenescence in Sepsis: From Cellular Mechanisms to Therapeutics,” Cell Death & Disease 16 (2025): 393.

[72] M. K. Sheats, “A Comparative Review of Equine SIRS, Sepsis, and Neutrophils,” Frontiers in Veterinary Science 6 (2019): 69.

[73] J. C. Cutrin, J. C. Alves-Filho, and B. Ryffel, “Editorial: Sepsis: Studying the Immune System to Highlight Biomarkers for Diagnosis, Prognosis and Personalized Treatments,” Frontiers in Immunology 14 (2023): 1325020.

[74] H. Sun, Q. Hong, C. Li, et al., “Immunosenescence in Sepsis: Molecular Mechanisms and Potential Therapeutic Targets,” Aging and Disease 17, no. 2 (2025): 780–811, https://doi.org/10.14336/AD.2025.0039.

[75] P. H. C. Leliefeld, C. M. Wessels, L. P. H. Leenen, L. Koenderman, and J. Pillay, “The Role of Neutrophils in Immune Dysfunction During Severe Inflammation,” Critical Care 20 (2016): 73.

[76] Z. Wang, W. Zhang, L. Chen, X. Lu, and Y. Tu, “Lymphopenia in Sepsis: A Narrative Review,” Critical Care 28 (2024): 315.

[77] M. D. Martin, V. P. Badovinac, and T. S. Griffith, “CD4 T Cell Responses and the Sepsis-Induced Immunoparalysis State,” Frontiers in Immunology 11 (2020): 1364.

[78] Y.-C. Liu, S.-T. Shou, and Y.-F. Chai, “Immune Checkpoints in Sepsis: New Hopes and Challenges,” International Reviews of Immunology 41 (2022): 207–216.

[79] R. Stienstra, R. T. Netea-Maier, N. P. Riksen, L. A. B. Joosten, and M. G. Netea, “Specific and Complex Reprogramming of Cellular Metabolism in Myeloid Cells During Innate Immune Responses,” Cell Metabolism 26 (2017): 142–156.

[80] Z. Wang and Z. Wang, “The Role of Macrophages Polarization in Sepsis-Induced Acute Lung Injury,” Frontiers in Immunology 14 (2023): 1209438.

[81] M. A. McGuckin, R. Eri, L. A. Simms, T. H. J. Florin, and G. Radford-Smith, “Intestinal Barrier Dysfunction in Inflammatory Bowel Diseases,” Inflammatory Bowel Diseases 15 (2009): 100–113.

[82] T. Oami, S. Abtahi, T. Shimazui, et al., “Claudin-2 Upregulation Enhances Intestinal Permeability, Immune Activation, Dysbiosis, and Mortality in Sepsis,” Proceedings of the National Academy of Sciences of the United States of America 121 (2024): e2217877121.

[83] L. W. Kaminsky, R. Al-Sadi, and T. Y. Ma, “IL-1β and the Intestinal Epithelial Tight Junction Barrier,” Frontiers in Immunology 12 (2021): 767456.

[84] A. T. Blikslager, A. J. Moeser, J. L. Gookin, S. L. Jones, and J. Odle, “Restoration of Barrier Function in Injured Intestinal Mucosa,” Physiological Reviews 87 (2007): 545–564.

[85] Y. Chen, W. Cui, X. Li, and H. Yang, “Interaction Between Commensal Bacteria, Immune Response and the Intestinal Barrier in Inflammatory Bowel Disease,” Frontiers in Immunology 12 (2021): 761981.

[86] S. K. Linden, P. Sutton, N. G. Karlsson, V. Korolik, and M. A. McGuckin, “Mucins in the Mucosal Barrier to Infection,” Mucosal Immunology 1 (2008): 183–197.

[87] J. Ewaschuk, R. Endersby, D. Thiel, et al., “Probiotic Bacteria Prevent Hepatic Damage and Maintain Colonic Barrier Function in a Mouse Model of Sepsis,” Hepatology 46 (2007): 841–850.

[88] W. Shen, H. Wang, J. Wang, et al., “Gut Microbiota Immaturity With DL-Endopeptidase Deficiency Links Antibiotic Use to Preterm Late-Onset Sepsis,” Cell Host & Microbe 34 (2026): 672–691.e13.

[89] E. M. Schill, E. L. Joyce, A. N. Floyd, et al., “Vancomycin-Induced Gut Microbial Dysbiosis Alters Enteric Neuron-Macrophage Interactions During a Critical Period of Postnatal Development,” Frontiers in Immunology 14 (2023): 1268909.

[90] A. Lockhart, D. Mucida, and A. M. Bilate, “Intraepithelial Lymphocytes of the Intestine,” Annual Review of Immunology 42 (2024): 289–316.

[91] H.-F. Bu, X. L. Zuo, X. Wang, et al., “Milk Fat Globule–EGF Factor 8/Lactadherin Plays a Crucial Role in Maintenance and Repair of Murine Intestinal Epithelium,” Journal of Clinical Investigation 117 (2007): 3673–3683.

[92] M. Sylvestre, S. E. Di Carlo, and L. Peduto, “Stromal Regulation of the Intestinal Barrier,” Mucosal Immunology 16 (2023): 221–231.

[93] Y. Chen, Z. Ye, U. Seidler, D. Tian, and F. Xiao, “Microenvironmental Regulation of Intestinal Stem Cells in the Inflamed Intestine,” Life Sciences 273 (2021): 119298.

[94] D. Zhao, V. Ravikumar, T. J. Leach, et al., “Inflammation-Induced Epigenetic Imprinting Regulates Intestinal Stem Cells,” Cell Stem Cell 31 (2024): 1447–1464.e6.

[95] S.-M. Chen, B. J. Guo, A. Q. Feng, X. L. Wang, S. L. Zhang, and C. Y. Miao, “Pathways Regulating Intestinal Stem Cells and Potential Therapeutic Targets for Radiation Enteropathy,” Molecular Biomedicine 5 (2024): 46.

[96] K. Nalapareddy, Y. Zheng, and H. Geiger, “Aging of Intestinal Stem Cells,” Stem Cell Reports 17 (2022): 734–740.

[97] M. C. Funk, J. G. Gleixner, F. Heigwer, et al., “Aged Intestinal Stem Cells Propagate Cell-Intrinsic Sources of Inflammaging in Mice,” Developmental Cell 58 (2023): 2914–2929.e7.

[98] A. Albillos, A. de Gottardi, and M. Rescigno, “The Gut-Liver Axis in Liver Disease: Pathophysiological Basis for Therapy,” Journal of Hepatology 72 (2020): 558–577.

[99] P. Strnad, F. Tacke, A. Koch, and C. Trautwein, “Liver - Guardian, Modifier and Target of Sepsis,” Nature Reviews. Gastroenterology & Hepatology 14 (2017): 55–66.

[100] G. Agirman, K. B. Yu, and E. Y. Hsiao, “Signaling Inflammation Across the Gut-Brain Axis,” Science 374 (2021): 1087–1092.

[101] X. Wang, X. Wen, S. Yuan, and J. Zhang, “Gut-Brain Axis in the Pathogenesis of Sepsis-Associated Encephalopathy,” Neurobiology of Disease 195 (2024): 106499.

[102] S. Carloni, A. Bertocchi, S. Mancinelli, et al., “Identification of a Choroid Plexus Vascular Barrier Closing During Intestinal Inflammation,” Science 374 (2021): 439–448.

[103] C. He, H. Shi, Z. Yu, et al., “The Progress of the Microbe-Gut-Brain Axis in Sepsis-Associated Encephalopathy,” Frontiers in Cellular and Infection Microbiology 15 (2025): 1587463.

[104] M. G. Gareau, “The Microbiota-Gut-Brain Axis in Sepsis-Associated Encephalopathy,” mSystems 7(2022): e00533-22.

[105] P. Passaglia, A. Kanashiro, H. Batista Silva, et al., “Diminazene Aceturate Attenuates Systemic Inflammation via Microbiota Gut-5-HT Brain-Spleen Sympathetic Axis in Male Mice,” Brain, Behavior, and Immunity 119 (2024): 105–119.

[106] L. Zhao, Z. Zhang, P. Wang, et al., “NHH Promotes Sepsis-Associated Encephalopathy With the Expression of AQP4 in Astrocytes Through the Gut-Brain Axis,” Journal of Neuroinflammation 21 (2024): 138.

[107] V. V. Giridharan, J. S. Generoso, L. Lence, et al., “A Crosstalk Between Gut and Brain in Sepsis-Induced Cognitive Decline,” Journal of Neuroinflammation 19 (2022): 114.

[108] Q. Zhang, C. Lu, W. Fan, J. Zhang, and Y. Yin, “Application Background and Mechanism of Short-Chain Fatty Acids in Sepsis-Associated Encephalopathy,” Frontiers in Cellular and Infection Microbiology 13 (2023): 1137161.

[109] T. J. Schuijt, J. M. Lankelma, B. P. Scicluna, et al., “The Gut Microbiota Plays a Protective Role in the Host Defence Against Pneumococcal Pneumonia,” Gut 65 (2016): 575–583.

[110] B. Xie, M. Wang, X. Zhang, et al., “Gut-Derived Memory γδ T17 Cells Exacerbate Sepsis-Induced Acute Lung Injury in Mice,” Nature Communications 15 (2024): 6737.

[111] Y. Tang, L. Chen, J. Yang, S. Zhang, J. Jin, and Y. Wei, “Gut Microbes Improve Prognosis of Klebsiella pneumoniae Pulmonary Infection Through the Lung-Gut Axis,” Frontiers in Cellular and Infection Microbiology 14 (2024): 1392376.

[112] Y. Jia, G. Zhu, C. Qiu, et al., “Pellino1 Orchestrates Gut-Kidney Axis to Perpetuate Septic Acute Kidney Injury Through Activation of STING Pathway and NLRP3 Inflammasome,” Life Sciences 345 (2024): 122604.

[113] Q. Chen, X. Liang, T. Wu, et al., “Integrative Analysis of Metabolomics and Proteomics Reveals Amino Acid Metabolism Disorder in Sepsis,” Journal of Translational Medicine 20 (2022): 123.

[114] X. Xu, Y. Pang, and X. Fan, “Mitochondria in Oxidative Stress, Inflammation and Aging: From Mechanisms to Therapeutic Advances,” Signal Transduction and Targeted Therapy 10 (2025): 190.

[115] G. Wang, F. Ma, K. Xie, et al., “Liensinine Alleviates Mouse Intestinal Injury Induced by Sepsis Through Inhibition of Oxidative Stress, Inflammation, and Cell Apoptosis,” International Immunopharmacology 127 (2024): 111335.

[116] S. Nesci and S. Rubattu, “UCP2, a Member of the Mitochondrial Uncoupling Proteins: An Overview From Physiological to Pathological Roles,” Biomedicine 12 (2024): 1307.

[117] B. Huang, G. Lin, F. Chen, et al., “UCP2 Knockout Exacerbates Sepsis-Induced Intestinal Injury by Promoting NLRP3-Mediated Pyroptosis,” International Immunopharmacology 141 (2024): 112935.

[118] Y. Wang, B. Tang, H. Li, et al., “A Small-Molecule Inhibitor of Keap1–Nrf2 Interaction Attenuates Sepsis by Selectively Augmenting the Antibacterial Defence of Macrophages at Infection Sites,” eBioMedicine 90 (2023): 104480.

[119] S. Gunne, U. Heinicke, M. J. Parnham, V. Laux, K. Zacharowski, and A. von Knethen, “Nrf2—A Molecular Target for Sepsis Patients in Critical Care,” Biomolecules 10 (2020): 1688.

[120] L. Xie, C. Zhou, Y. Wu, et al., “Wenqingyin Suppresses Ferroptosis in the Pathogenesis of Sepsis-Induced Liver Injury by Activating the Nrf2-Mediated Signaling Pathway,” Phytomedicine 114 (2023): 154748.

[121] J. Fu, G. Li, X. Wu, and B. Zang, “Sodium Butyrate Ameliorates Intestinal Injury and Improves Survival in a Rat Model of Cecal Ligation and Puncture-Induced Sepsis,” Inflammation 42 (2019): 1276–1286.

[122] M. J. Morgan and Z. Liu, “Crosstalk of Reactive Oxygen Species and NF-κB Signaling,” Cell Research 21 (2011): 103–115.

[123] L. Zhan, J. Zheng, J. Meng, D. Fu, L. Pang, and C. Ji, “Toll-Like Receptor 4 Deficiency Alleviates Lipopolysaccharide-Induced Intestinal Barrier Dysfunction,” Biomedicine & Pharmacotherapy 155 (2022): 113778.

[124] S. H. Kathem, Y. S. Nasrawi, S. H. Mutlag, and S. M. Nauli, “Limonene Exerts Anti-Inflammatory Effect on LPS-Induced Jejunal Injury in Mice by Inhibiting NF-κB/AP-1 Pathway,” Biomolecules 14 (2024): 334.

[125] J. A. Dominguez, et al., “Inhibition of IKKß in Enterocytes Exacerbates Sepsis-Induced Intestinal Injury and Worsens Mortality,” Critical Care Medicine 41 (2013):275–285.

[126] N. Liu, X. Pang, H. Zhang, and P. Ji, “The cGAS-STING Pathway in Bacterial Infection and Bacterial Immunity,” Frontiers in Immunology 12 (2021): 814709.

[127] T. Yu, J. S. Fleishman, H. Wang, X. Liu, and L. Huo, “cGAS-STING Targeting Offers Novel Therapeutic Regimen in Sepsis-Associated Organ Dysfunction,” Cell Biology and Toxicology 41 (2025): 113.

[128] S. Sun, Z. Duan, X. Wang, et al., “Neutrophil Extracellular Traps Impair Intestinal Barrier Functions in Sepsis by Regulating TLR9-Mediated Endoplasmic Reticulum Stress Pathway,” Cell Death & Disease 12 (2021): 606.

[129] H.-F. Zhang, H. B. Zhang, X. P. Wu, Y. L. Guo, W. D. Cheng, and F. Qian, “Fisetin Alleviates Sepsis-Induced Multiple Organ Dysfunction in Mice via Inhibiting p38 MAPK/MK2 Signaling,” Acta Pharmacologica Sinica 41 (2020): 1348–1356.

[130] T. Tan, J. Li, W. Fan, et al., “Tetrahedral Framework Nucleic Acid Relieves Sepsis-Induced Intestinal Injury by Regulating M2 Macrophages,” Cell Proliferation 58 (2025): e13803.

[131] F. Tan, Y. Cao, L. Zheng, et al., “Diabetes Exacerbated Sepsis-Induced Intestinal Injury by Promoting M1 Macrophage Polarization via miR-3061/Snail1 Signaling,” Frontiers in Immunology 13 (2022): 922614.

[132] D. Patoli, F. Mignotte, V. Deckert, et al., “Inhibition of Mitophagy Drives Macrophage Activation and Antibacterial Defense During Sepsis,” Journal of Clinical Investigation 130 (2020): 5858–5874.

[133] F. V. Sjaastad, S. A. Condotta, J. A. Kotov, et al., “Polymicrobial Sepsis Chronic Immunoparalysis Is Defined by Diminished ag-Specific T Cell-Dependent B Cell Responses,” Frontiers in Immunology 9 (2018): 2532.

[134] F. V. Sjaastad, T. A. Kucaba, T. Dileepan, et al., “Polymicrobial Sepsis Impairs Antigen-Specific Memory CD4 T Cell-Mediated Immunity,” Frontiers in Immunology 11 (2020): 1786.

[135] P. Zhao, J. Li, P. He, et al., “NUFIP1-Mediated Ribophagy Alleviates PANoptosis of CD4+ T Lymphocytes in Sepsis via the cGAS-STING Pathway,” Research 8 (2025): 0895.

[136] J. Domínguez-Andrés, B. Novakovic, Y. Li, et al., “The Itaconate Pathway Is a Central Regulatory Node Linking Innate Immune Tolerance and Trained Immunity,” Cell Metabolism 29 (2019): 211–220.e5.

[137] M. Willers, T. Ulas, L. Völlger, et al., “S100A8 and S100A9 Are Important for Postnatal Development of Gut Microbiota and Immune System in Mice and Infants,” Gastroenterology 159 (2020): 2130–2145.e5.

[138] A. Arapis, D. Panagiotopoulos, and E. J. Giamarellos-Bourboulis, “Recent Advances of Precision Immunotherapy in Sepsis,” Burns & Trauma 13 (2025): tkaf001.

[139] L. K. Billingham, J. S. Stoolman, K. Vasan, et al., “Mitochondrial Electron Transport Chain Is Necessary for NLRP3 Inflammasome Activation,” Nature Immunology 23 (2022): 692–704.

[140] S. Huang, Z. Zeng, Y. Chu, et al., “Mitigation of Lipopolysaccharide-Induced Intestinal Injury in Rats by Chimonanthus Nitens Oliv. Essential Oil via Suppression of Mitochondrial Fusion Protein Mitofusin 2 (MFN2)-mediated Mitochondrial-Associated Endoplasmic Reticulum Membranes (MAMs) Formation,” Journal of Ethnopharmacology 337 (2025): 118856.

[141] X. Liu, Y. Liu, X. Su, L. Jiang, G. Tang, and Y. Wang, “Geranylgeranylacetone Mitigates Sepsis-Associated Intestinal Injury Through CHIP-Dependent Anti-Inflammation and Anti-Oxidative Effect,” International Immunopharmacology 135 (2024): 112263.

[142] M. Wang, J. Liao, W. Lin, et al., “YL-109 Attenuates Sepsis-Associated Multiple Organ Injury Through Inhibiting the ERK/AP-1 Axis and Pyroptosis by Upregulating CHIP,” Biomedicine & Pharmacotherapy 175 (2024): 116633.

[143] Z. Xu, D. Li, W. Qu, et al., “Card9 Protects Sepsis by Regulating Ripk2-Mediated Activation of NLRP3 Inflammasome in Macrophages,” Cell Death & Disease 13 (2022): 502.

[144] S. Ye, X. Qi, Y. Liu, L. Zhuang, and Z. Gu, “RIP1/3-Dependent Programmed Necrosis Induces Intestinal Injury in Septic Rats,” Acta Biochimica et Biophysica Sinica 56 (2023): 106–113.

[145] X. Zhang, J. Wu, Q. Liu, et al., “RIPK3–MLKL Necroptotic Signalling Amplifies STING Pathway and Exacerbates Lethal Sepsis,” Clinical and Translational Medicine 13 (2023): e1334.

[146] Y.-K. Chen, Y. K. Xu, H. Zhang, et al., “Emodin Alleviates Jejunum Injury in Rats With Sepsis by Inhibiting Inflammation Response,” Biomedicine & Pharmacotherapy 84 (2016): 1001–1007.

[147] J. Wu, X. Xu, J. Duan, et al., “EFHD2 Suppresses Intestinal Inflammation by Blocking Intestinal Epithelial Cell TNFR1 Internalization and Cell Death,” Nature Communications 15 (2024): 1282.

[148] J.-K. Sun, X. T. Huangfu, X. Yin, et al., “Ferroptosis Is Involved in the IL-9-Induced Intestinal Barrier Injury in Sepsis: An Experimental Animal and Translational Study,” International Journal of Surgery 111 (2025): 4314–4324.

[149] J. Lee, Y. Seo, and J.-L. Roh, “Ferroptosis and Nrf2 Signaling in Head and Neck Cancer: Resistance Mechanisms and Therapeutic Prospects,” Antioxidants 14 (2025): 993.

[150] C. Lee, J. E. Kim, Y. E. Cha, et al., “IFN-γ-Induced Intestinal Epithelial Cell-Type-Specific Programmed Cell Death: PANoptosis and Its Modulation in Crohn's Disease,” Frontiers in Immunology 16 (2025): 1523984.

[151] J. Joffre, J. Hellman, C. Ince, and H. Ait-Oufella, “Endothelial Responses in Sepsis,” American Journal of Respiratory and Critical Care Medicine 202 (2020): 361–370.

[152] S. Yang, J. Guo, Z. Kong, et al., “Causal Effects of Gut Microbiota on Sepsis and Sepsis-Related Death: Insights From Genome-Wide Mendelian Randomization, Single-Cell RNA, Bulk RNA Sequencing, and Network Pharmacology,” Journal of Translational Medicine 22 (2024): 10.

[153] J. S. Ayres, N. J. Trinidad, and R. E. Vance, “Lethal Inflammasome Activation by a Multi-Drug Resistant Pathobiont Upon Antibiotic Disruption of the Microbiota,” Nature Medicine 18 (2012): 799–806.

[154] F. Deng, J. J. Hu, Z. B. Lin, et al., “Gut Microbe-Derived Milnacipran Enhances Tolerance to Gut Ischemia/Reperfusion Injury,” Cell Reports Medicine 4 (2023): 100979.

[155] R. C. Keskey, J. Xiao, S. Hyoju, et al., “Enterobactin Inhibits Microbiota-Dependent Activation of AhR to Promote Bacterial Sepsis in Mice,” Nature Microbiology 10 (2025): 388–404.

[156] P. Bhanja, A. Norris, P. Gupta-Saraf, A. Hoover, and S. Saha, “BCN057 Induces Intestinal Stem Cell Repair and Mitigates Radiation-Induced Intestinal Injury,” Stem Cell Res Ther 9 (2018): 26.

[157] W. Zhang, B. Zhou, X. Yang, et al., “Exosomal circEZH2_005, an Intestinal Injury Biomarker, Alleviates Intestinal Ischemia/Reperfusion Injury by Mediating Gprc5a Signaling,” Nature Communications 14 (2023): 5437.

[158] Z. Liu, J. Jiang, W. Dai, et al., “MicroRNA-674-5p Induced by HIF-1α Targets XBP-1 in Intestinal Epithelial Cell Injury During Endotoxemia,” Cell Death Discov 6 (2020): 44.

[159] H. Li, J. Lu, H. Li, A. Duan, Y. Wang, and D. Zhang, “Association Between Nutrition Support and Acute Gastrointestinal Injury in Critically Ill Patients During the First 72 Hours,” Clinical Nutrition 40 (2021): 217–221.

[160] M. Tyszko, A. Lemańska-Perek, J. Śmiechowicz, et al., “Citrulline, Intestinal Fatty Acid-Binding Protein and the Acute Gastrointestinal Injury Score as Predictors of Gastrointestinal Failure in Patients With Sepsis and Septic Shock,” Nutrients 15 (2023): 2100.

[161] T. Barichello, J. S. Generoso, M. Singer, and F. Dal-Pizzol, “Biomarkers for Sepsis: More Than Just Fever and Leukocytosis-a Narrative Review,” Critical Care 26 (2022): 14.

[162] Z. Chang, J. Lu, Q. Zhang, et al., “Clinical Biomarker Profiles Reveals Gender Differences and Mortality Factors in Sepsis,” Frontiers in Immunology 15 (2024): 1413729.

[163] J.-K. Sun, J. Zhou, X. P. Sun, et al., “Interleukin-9 Promotes Intestinal Barrier Injury of Sepsis: A Translational Research,” Journal of Intensive Care 9 (2021): 37.

[164] F. Haedge, P. A. Reuken, J. Reißing, et al., “Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut-Vascular Barrier Damage Across Stages of Cirrhosis,” Liver International 45 (2025): e70119.

[165] J. Parantainen, G. Barreto, T. E. Strandberg, N. Mars, K. Nurmi, and K. K. Eklund, “Increased Intestinal Mucosal Permeability and Metabolic Endotoxemia Predict the Risk of Cardiovascular Mortality,” Atherosclerosis 405 (2025): 119220.

[166] P. Gu, R. Liu, Q. Yang, et al., “A Metabolite From Commensal Candida albicans Enhances the Bactericidal Activity of Macrophages and Protects Against Sepsis,” Cellular & Molecular Immunology 20 (2023): 1156–1170.

[167] S. Sun, D. Wang, D. Dong, et al., “Altered Intestinal Microbiome and Metabolome Correspond to the Clinical Outcome of Sepsis,” Critical Care 27 (2023): 127.

[168] Z. Sun, Z. Ning, Q. Wu, L. Li, A. C. Doxey, and D. Figeys, “Peptide Abundance Correlations in Metaproteomics Enhance Taxonomic and Functional Analysis of the Human Gut Microbiome,” NPJ Biofilms Microbiomes 11 (2025): 166.

[169] A. P. de Porto, et al., “Fecal Metabolite Profiling Identifies Critically Ill Patients With Increased 30-Day Mortality,” Science Advances 11(2025): eadt1466.

[170] J. Xu, J. Li, X. Kong, et al., “Dysbiosis and Metabolic Pathway Shifts in the Gut Microbiome of Children With Sepsis: A Comparative Analysis,” Frontiers in Microbiology 16 (2025): 1715990.

[171] Y. Luo, J. Gao, X. Su, et al., “Unraveling the Immunological Landscape and Gut Microbiome in Sepsis: A Comprehensive Approach to Diagnosis and Prognosis,” eBioMedicine 113 (2025): 105586.

[172] H. Liang, X. Ding, S. Liu, et al., “Aging-Caused the Changes of the Gut Microbiota Drive Intestinal Barrier Dysfunction and Increase Sepsis Susceptibility,” Gut Microbes 18 (2026): 2630475.

[173] R. R. de Kroon, et al., “The Potential of Fecal Volatile Organic Compound Analysis for the Early Diagnosis of Late-Onset Sepsis in Preterm Infants: A Narrative Review,” Sensors 24 (2024): 3162.

[174] C. Willemart, M. Strazisar, T. de Pooter, et al., “Nanopore Sequencing Enables Tissue-Of-Origin and Pathogen Detection in Plasma Cell-Free DNA From Critically Ill Patients,” Cell Death Discov 11 (2025): 484.

[175] Y. Gao, H. Chen, R. Wu, and Z. Zhou, “AI-Driven Multi-Omics Profiling of Sepsis Immunity in the Digestive System,” Frontiers in Immunology 16 (2025): 1590526.

[176] D. Song, X. Zong, H. Zhang, et al., “Antimicrobial Peptide Cathelicidin-BF Prevents Intestinal Barrier Dysfunction in a Mouse Model of Endotoxemia,” International Immunopharmacology 25 (2015): 141–147.

[177] T. Liu, X. Tang, Y. Cui, et al., “Fibroblast Growth Factor 19 Improves LPS-Induced Lipid Disorder and Organ Injury by Regulating Metabolomic Characteristics in Mice,” Oxidative Medicine and Cellular Longevity 2022 (2022): 9673512.

[178] J. He, Y. Zhang, Y. Jing, et al., “FXR Protects Against Neonatal Sepsis by Enhancing the Immunosuppressive Function of MDSCs,” Cellular & Molecular Immunology 22 (2025): 661–673.

[179] J. Yang, R. Zhang, H. Zhao, et al., “Bioinspired Copper Single-Atom Nanozyme as a Superoxide Dismutase-Like Antioxidant for Sepsis Treatment,” Exploration 2 (2022): 20210267.

[180] W. Z. Tian, Q. Yue, W. Fei, P. Z. Yao, R. Q. Han, and J. Tang, “PE (0:0/14:0), an Endogenous Metabolite of the Gut Microbiota, Exerts Protective Effects Against Sepsis-Induced Intestinal Injury by Modulating the AHR/CYP1A1 Pathway,” Clinical Science (London, England) 137 (2023): 1753–1769.

[181] Z. Li, X. Zhang, H. Zhou, W. Liu, and J. Li, “Exogenous S-Nitrosoglutathione Attenuates Inflammatory Response and Intestinal Epithelial Barrier Injury in Endotoxemic Rats,” Journal of Trauma and Acute Care Surgery 80 (2016): 977–984.

[182] A. Brandt, A. Baumann, A. Hernández-Arriaga, et al., “Impairments of Intestinal Arginine and NO Metabolisms Trigger Aging-Associated Intestinal Barrier Dysfunction and ‘Inflammaging’,” Redox Biology 58 (2022): 102528.

[183] Y. Wu, C. S. Chung, Y. Chen, et al., “A Novel Role for Programmed Cell Death Receptor Ligand-1 in Sepsis-Induced Intestinal Dysfunction,” Molecular Medicine 22 (2016): 830–840.

[184] H. Yang, Z. Song, H. Jin, Y. Cui, M. Hou, and Y. Gao, “Protective Effect of rhBNP on Intestinal Injury in the Canine Models of Sepsis,” International Immunopharmacology 19 (2014): 262–266.

[185] Y.-L. Chen, Y. J. Xie, Z. M. Liu, et al., “Omega-3 Fatty Acids Impair miR-1-3p-Dependent Notch3 Down-Regulation and Alleviate Sepsis-Induced Intestinal Injury,” Molecular Medicine 28 (2022): 9.

[186] W. J. Wiersinga and T. van der Poll, “Immunopathophysiology of Human Sepsis,” eBioMedicine 86 (2022): 104363.

[187] K. Leventogiannis, E. Kyriazopoulou, N. Antonakos, et al., “Toward Personalized Immunotherapy in Sepsis: The PROVIDE Randomized Clinical Trial,” Cell Reports Medicine 3 (2022): 100817.

[188] X. Du, et al., “Immunomodulatory Nanozymes Eradicate Intracellular Infections and Rescue Immunoparalysis for Treating Multidrug-Resistant Bacterial Sepsis,” Exploration 5 (2025): 20250127.

[189] D. P. Schrijver, R. J. Röring, J. Deckers, et al., “Resolving Sepsis-Induced Immunoparalysis via Trained Immunity by Targeting Interleukin-4 to Myeloid Cells,” Nature Biomedical Engineering 7 (2023): 1097–1112.

[190] J. W. Hwang, M. J. Lee, T. N. Chung, et al., “The Immune Modulatory Effects of Mitochondrial Transplantation on Cecal Slurry Model in Rat,” Critical Care 25 (2021): 20.

[191] C. Zhang, Z. Fu, Q. Liu, et al., “Bioprinted M2 Macrophage-Derived Extracellular Vesicle Mimics Attenuate Foreign Body Reaction and Enhance Vascularized Tissue Regeneration,” Biofabrication 17 (2025): 035007.

[192] Y. Lee, N. Kamada, and J. J. Moon, “Oral Nanomedicine for Modulating Immunity, Intestinal Barrier Functions, and Gut Microbiome,” Advanced Drug Delivery Reviews 179 (2021): 114021.

[193] Y. Liu, Q. Xu, Y. Wang, et al., “Necroptosis Is Active and Contributes to Intestinal Injury in a Piglet Model With Lipopolysaccharide Challenge,” Cell Death & Disease 12 (2021): 62.

[194] Y. Yan, B. Li, Q. Gao, et al., “Intestine-Decipher Engineered Capsules Protect Against Sepsis-Induced Intestinal Injury via Broad-Spectrum Anti-Inflammation and Parthanatos Inhibition,” Advanced Science 12 (2025): e2412799.

[195] J. Yin, W. Sun, X. Yu, et al., “Lacticaseibacillus Rhamnosus TR08 Alleviated Intestinal Injury and Modulated Microbiota Dysbiosis in Septic Mice,” BMC Microbiology 21 (2021): 249.

[196] H. Xuan, S. Umar, C. Zhong, et al., “Lactobacillus rhamnosus Modulates Murine Neonatal Gut Microbiota and Inflammation Caused by Pathogenic Escherichia coli,” BMC Microbiology 24 (2024): 452.

[197] Y. Yue, et al., “Bifidobacterium bifidum E3 Combined With Bifidobacterium longum Subsp. Infantis E4 Improves LPS-Induced Intestinal Injury by Inhibiting the TLR4/NF-κB and MAPK Signaling Pathways in Vivo,” Journal of Agricultural and Food Chemistry 71 (2023): 8915–8930.

[198] Y. Chen, K. Sun, Y. Qi, J. Tang, H. Zhu, and Z. Wang, “L-Valine Derived From the Gut Microbiota Protects Sepsis-Induced Intestinal Injury and Negatively Correlates With the Severity of Sepsis,” Frontiers in Immunology 15 (2024): 1424332.

[199] K. A. Muñoz, R. J. Ulrich, A. K. Vasan, et al., “A Gram-Negative-Selective Antibiotic That Spares the Gut Microbiome,” Nature 630 (2024): 429–436.

[200] A. Petrovic Fabijan, R. C. Y. Lin, J. Ho, et al., “Safety of Bacteriophage Therapy in Severe Staphylococcus aureus Infection,” Nature Microbiology 5 (2020): 465–472.

[201] P. Singh, E. J. Alm, J. M. Kelley, et al., “Effect of Antibiotic Pretreatment on Bacterial Engraftment After Fecal Microbiota Transplant (FMT) in IBS-D,” Gut Microbes 14 (2022): 2020067.

[202] S. Huang, S. Zhao, H. Zhao, M. Wen, and Z. Guo, “Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application,” Exploration 5 (2025): e20240045.

[203] Q. Yao, T. Liu, J. Wen, et al., “SpyTag-PEGylated Probiotics Delivering IL-1Ra Modulate Gut-Lung Crosstalk to Mitigate Septic Lung Injury,” Journal of Controlled Release 386 (2025): 114163.

[204] F. Siwczak, E. Loffet, M. Kaminska, H. Koceva, M. M. Mahe, and A. S. Mosig, “Intestinal Stem Cell-On-Chip to Study Human Host-Microbiota Interaction,” Frontiers in Immunology 12 (2021): 798552.

[205] D. Zheng, H. Zhou, H. Wang, et al., “Mesenchymal Stem Cell-Derived Microvesicles Improve Intestinal Barrier Function by Restoring Mitochondrial Dynamic Balance in Sepsis Rats,” Stem Cell Res Ther 12 (2021): 299.

[206] Q. Shen, Z. Huang, J. Yao, and Y. Jin, “Extracellular Vesicles-Mediated Interaction Within Intestinal Microenvironment in Inflammatory Bowel Disease,” Journal of Advanced Research 37 (2022): 221–233.

[207] F. Ahangari, S. Soudi, S. Ghaffari Khaligh, et al., “Combinational Therapy of Mesenchymal Stem Cell-Derived Extracellular Vesicles and Azithromycin Improves Clinical and Histopathological Recovery in CLP Sepsis Model,” International Immunopharmacology 139 (2024): 112732.

[208] L. Chen, S. Li, C. Peng, et al., “Lactobacillus rhamnosus GG Promotes Recovery of the Colon Barrier in Septic Mice Through Accelerating ISCs Regeneration,” Nutrients 15 (2023): 672.

[209] Q. Che, T. Luo, J. Shi, Y. He, and D.-L. Xu, “Mechanisms by Which Traditional Chinese Medicines Influence the Intestinal Flora and Intestinal Barrier,” Frontiers in Cellular and Infection Microbiology 12 (2022): 863779.

[210] D. Wang, Y. Kuang, Q. Lv, et al., “Selenium-Enriched Cardamine Violifolia Protects Against Sepsis-Induced Intestinal Injury by Regulating Mitochondrial Fusion in Weaned Pigs,” Science China. Life Sciences 66 (2023): 2099–2111.

[211] Y. Wang, G. Liu, F. Qiu, et al., “Corilagin Alleviated Intestinal Ischemia-Reperfusion Injury by Modulating Endoplasmic Reticulum Stress via Bonding With Bip,” Phytomedicine: international journal of phytotherapy and phytopharmacology 135 (2024): 156011.

[212] X. Fan, C. Mai, L. Zuo, et al., “Herbal Formula BaWeiBaiDuSan Alleviates Polymicrobial Sepsis-Induced Liver Injury via Increasing the Gut Microbiota Lactobacillus Johnsonii and Regulating Macrophage Anti-Inflammatory Activity in Mice,” Acta Pharmaceutica Sinica B 13 (2023): 1164–1179.

[213] Z. Li, M. Gao, B. Yang, et al., “Naringin Attenuates MLC Phosphorylation and NF-κB Activation to Protect Sepsis-Induced Intestinal Injury via RhoA/ROCK Pathway,” Biomedicine & Pharmacotherapy 103 (2018): 50–58.

[214] Z.-L. Li, B. C. Yang, M. Gao, X. F. Xiao, S. P. Zhao, and Z. L. Liu, “Naringin Improves Sepsis-Induced Intestinal Injury by Modulating Macrophage Polarization via PPARγ/miR-21 Axis,” Molecular Therapy - Nucleic Acids 25 (2021): 502–514.

[215] H. Xu, T. Q. He, S. Y. Chen, et al., “Isoquercitrin Mitigates Intestinal Ischemia-Reperfusion Injury by Regulating Intestinal Flora and Inhibiting NLRP3 Inflammasome Activation,” Redox Biology 86 (2025): 103803.

Rights & permissions

2026 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.